KR810001174B1 - Process for preparing dithiepino(1,4)(2,3-c)pyrrole derivatives - Google Patents

Process for preparing dithiepino(1,4)(2,3-c)pyrrole derivatives Download PDF

Info

Publication number
KR810001174B1
KR810001174B1 KR1019810002605A KR810002605A KR810001174B1 KR 810001174 B1 KR810001174 B1 KR 810001174B1 KR 1019810002605 A KR1019810002605 A KR 1019810002605A KR 810002605 A KR810002605 A KR 810002605A KR 810001174 B1 KR810001174 B1 KR 810001174B1
Authority
KR
South Korea
Prior art keywords
group
dithiepino
pyrrole
general formula
oxo
Prior art date
Application number
KR1019810002605A
Other languages
Korean (ko)
Inventor
진마르트 크로오드
레이저 아안드레이
Original Assignee
로오느-푸우랜크 인더스트리이즈
쟈안 허어슨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR7700357A external-priority patent/KR810000933B1/en
Application filed by 로오느-푸우랜크 인더스트리이즈, 쟈안 허어슨 filed Critical 로오느-푸우랜크 인더스트리이즈
Priority to KR1019810002605A priority Critical patent/KR810001174B1/en
Application granted granted Critical
Publication of KR810001174B1 publication Critical patent/KR810001174B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Title compds. (I; A = ph, pyrid-2-yl, quinol-2-yl, 1,8-naphthiridin-2-yl; R = H, Me, aryl, propionyl, butylyl) useful as tranguilizer, were prepd. by reaction of II and III (Ar = C1-4 alkyl or nitro-substituted phenyl). Thus, 1.1 g II(R = Me) was added to 1.6 g III(A = 5-chloropyrid-2-yl; Ar = ph) in 20 cc CH3CN followed by stirring, extracting and washing to give 0.7 g I(A = 5-chloropyrid-2-yl; Ar = ph; R = Me).

Description

디티에피노[1,4][2,3-C]피롤유도체의 제조방법Method for preparing dithiepino [1,4] [2,3-C] pyrrole derivatives

본 발명은 신규하고 치료적이고 유용한 다음 일반식(I)의 디티에피노〔1,4〕 〔2,3-C〕피롤 유도체 및 그 산부가염의 제조방법에 관한 것이다.The present invention relates to novel, therapeutic and useful dithiepino [1,4] [2,3-C] pyrrole derivatives of the general formula (I) and methods for preparing acid addition salts thereof.

Figure kpo00001
Figure kpo00001

상기식에서 A는 페닐, 피리드-2-일, 퀴놀-2-일 또는 1,8-나프티리딘-2-일기이며 각각 할로겐원자(바람직하기로는 염소원자),C1-4의 알킬기(바람직하기로는 메틸기) C1-4의 알콕시기(바람직하기로는 메톡시기), 시아노기 또는 니트로기의 임의 치환될 수 있고 R은 수소원자 또는 C1-4의 알킬기(바람직하기로는 메틸기), C2-4의 알케닐기(바람직하기로는 알릴기) 또는 C1-4의 알카노일기(예를들면, 프로피오닐 또는 부티릴기)이다.Wherein A is a phenyl, pyrid-2-yl, quinol-2-yl or 1,8-naphthyridin-2-yl group, each of which is a halogen atom (preferably a chlorine atom), an alkyl group of C 1-4 (preferably Is a methyl group) C 1-4 alkoxy group (preferably methoxy group), cyano group or nitro group may be optionally substituted and R is a hydrogen atom or C 1-4 alkyl group (preferably methyl group), C 2- 4 is an alkenyl group (preferably allyl group) or a C 1-4 alkanoyl group (for example, propionyl or butyryl group).

본 발명의 특징이 따르면, 다음 일반식(II)의 피페라진과According to a feature of the invention, piperazine of the following general formula (II)

Figure kpo00002
Figure kpo00002

(상기식에서 R은 전술한 바와 같다.)다음 일반식(Ⅲ)의 혼합탄산염을 반응시켜 일반식(I)의 화합물을 제조한다.(Wherein R is as described above.) A compound of formula (I) is prepared by reacting the mixed carbonate of formula (III).

Figure kpo00003
Figure kpo00003

(상기식에서 A는 전술한 바와 같고, Ar은 C1-4의 알킬기 또는 니트로기의 임의 치환되는 페닐기이다)(Wherein A is as defined above and Ar is an optionally substituted phenyl group of a C 1-4 alkyl group or nitro group)

반응은 일반적으로 0-50℃에서 아세토니트릴 같은 무수 유기용매중에서 시행 할 수 있다.The reaction can generally be carried out in anhydrous organic solvents such as acetonitrile at 0-50 ° C.

일반식(Ⅲ)의 혼합 탄산염류는 다음 일반식(Ⅳ)의 클로로포르메이트The mixed carbonates of the general formula (III) are chloroformate of the following general formula (IV)

Figure kpo00004
Figure kpo00004

(Ar은 전술한 바와 같다)를 일반식(Ⅴ)의 디티에피노〔1,4〕〔2,3- C〕피롤 유도체와 반응시킴으로써 제조할 수 있다.(Ar is as described above) can be prepared by reacting with a dithi epino [1,4] [2,3-C] pyrrole derivative of the general formula (V).

Figure kpo00005
Figure kpo00005

(A는 전술한 바와 같다)(A is as described above)

이 반응은 일반적으로 알카리성 축합제 존재하에 피리딘 같은 염기성 유기용매 또는 테트라하이드로 푸란 같은 유기용매중에서 시행할 수 있다.This reaction can generally be carried out in a basic organic solvent such as pyridine or in an organic solvent such as tetrahydrofuran in the presence of an alkaline condensing agent.

일반식(Ⅴ)의 디티에피노〔1,4〕〔2,3- C〕피롤 유도체는 다음 일반식(Ⅵ)의 이미드를 부분 환원시켜 제조할 수 있다.Dithiepino [1,4] [2,3-C] pyrrole derivatives of the general formula (V) can be prepared by partially reducing the imide of the following general formula (VI).

Figure kpo00006
Figure kpo00006

(상기식에서 A는 전술한 바와 같다)(A is as described above)

환원은 일반적으로 유기용매 또는 예를들면, 디옥산-테트라하이드로푸란 또는 디옥산-메탄올 또는 디옥산-물 또는 메탄올-물 또는 에탄올-물 혼합물 같은 물-유기용액중에서 알카리금속 보로하이드라이드로 효과적으로 시행할 수 있다.Reduction is generally effected effectively with alkali metal borohydrides in organic solvents or in water-organic solutions such as, for example, dioxane-tetrahydrofuran or dioxane-methanol or dioxane-water or methanol-water or ethanol-water mixtures. can do.

일반식(Ⅵ)의 아마이드류는 다음 일반식(Ⅶ)의 아민 화합물을Amides of the general formula (VI) are amine compounds of the following general formula (VII)

Figure kpo00007
Figure kpo00007

(상기식에서 A는 전술한 바와 같다)(A is as described above)

6,7-디하이드로-5H-1,4-디티에핀-2,3-디카르복실산의 무수물과 반응시켜 제조할 수 있다. 반응은 일반적으로 초산, 디메틸 포름아마이드, 아세토니트릴 또는 디페닐 에텔 또는 이러한 용매들의 혼합물 중에서, 디사이클로헥실카보디이미드 또는 3-(3-디에틸아미노프로필)-1-이소프로필카보디이미드 같은 카보디이미드 존재하에 또는 부재하에 반응물을 가열시킴으로써 시행할 수 있다.It can be prepared by reacting with anhydrides of 6,7-dihydro-5H-1,4-dithiene-2,3-dicarboxylic acid. The reaction is usually carried out in a carbohydrate such as dicyclohexylcarbodiimide or 3- (3-diethylaminopropyl) -1-isopropylcarbodiimide, in acetic acid, dimethyl formamide, acetonitrile or diphenyl ether or mixtures of these solvents. This can be done by heating the reactants in the presence or absence of bodyimide.

6,7-디하이드로-5H-1,4-디티에핀-2,3-디카르복실산의 무수물은 산매질에서 6,7-디하이드로-5H-1,4-디티에핀-2,3-디카보니트릴을 가수분해시켜 제조할 수 있다.The anhydrides of 6,7-dihydro-5H-1,4-dithiene-2,3-dicarboxylic acid are 6,7-dihydro-5H-1,4-dithiene-2, It can be prepared by hydrolysis of 3-dicarbonitrile.

일반적으로 이 반응은 100-125℃에서 약 20N 황산중에서 더 잘 시행할 수 있다.In general, this reaction can be performed better in about 20N sulfuric acid at 100-125 ℃.

6,7-디하이드로-5H-1,4-디티에핀-2,3-디카보니트릴은 1,3-디브로모프로판을 2,3-디메르캅토말 레오니트릴의 디소디움염에 작용시켜 제조할 수 있다. 이 반응은 일반적으로 20℃와 반응 혼합물의 비등점 사이의 온도에서 1,2-디메톡시에탄 또는 디메틸포름아마이드와 같은 불활성 유기용매중에서 시행할 수 있다.6,7-dihydro-5H-1,4-dithipine-2,3-dicarbonitrile acts on 1,3-dibromopropane to disodium salt of 2,3-dimercaptomalonitrile Can be prepared. This reaction can generally be carried out in an inert organic solvent such as 1,2-dimethoxyethane or dimethylformamide at temperatures between 20 ° C. and the boiling point of the reaction mixture.

2,3-디메르캅토말레오니트릴의 디소움염은 Helv. Chim. Acta 52,2228 (1969)에 기술된 에이지 알 쉬 바이저의 방법에 따라 제조할 수 있다.The disodium salt of 2,3-dimercaptomalenitrile is Helv. Chim. It may be prepared according to the method of Age Alsch visor described in Acta 52,2228 (1969).

R이 알카노일기인 일반식 II 의 피페라진 유도체들은 다음 일반식(Ⅷ)의 산을Piperazine derivatives of the general formula II wherein R is an alkanoyl group are represented by the acid of the general formula

R2-COOH (VIII)R 2 -COOH (VIII)

(상기식에서 R2는 수소원자 또는 C1-3의 알킬기이다)(Wherein R 2 is a hydrogen atom or an alkyl group of C 1-3 )

또는 할라이드, 에스테르, 무수물, 혼합 무수물(mixed anhydride) 아마이드 또는 아자이드와 같은 산의 유도체의 작용에 의한 것과 같은 아마이드류 제조에 있어서 공지된 방법 그 자체를 피페라진에 응용하여 제조할 수 있다. 일반식(II)의 피페라진 유도체는 동시에 생성되는 디치환된 피페라진으로부터 물리적 또는 화학적 방법을 응용하여 분리시킬 수 있다.Or a known method itself in the production of amides, such as by the action of derivatives of acids such as halides, esters, anhydrides, mixed anhydride amides or azides. The piperazine derivatives of formula (II) can be separated from the disubstituted piperazine produced simultaneously by physical or chemical methods.

전술한 방법으로 얻은 일반식 I의 디티에피노〔1,4〕〔2,3- C〕피를 유도체는 결정화 또는 크로마토그라피 같은 물리적 방법 또는 염의 형성, 염의 결정화 및 알카리 매질에서의 염의 분해 같은 화학적 방법으로 정제할 수 있다. 전술한 화학적 방법을 시행함에 있어서 염의 음이온의 성질은 중요하지 않으며, 유일한 요구 조건은 염의 윤곽이 뚜렷하고 쉽게 결정화할 수 있어야 한다는 것이다.The dithiepino [1,4] [2,3-C] pyrido derivatives of the general formula I obtained by the above-mentioned methods may be used in chemical methods such as the formation of salts, crystallization of salts and decomposition of salts in alkaline media, or physical methods such as crystallization or chromatography. It can be purified by the method. The nature of the anions of the salts is not critical to the practice of the above-mentioned chemical methods, and the only requirement is that the salts be outlined and easily crystallized.

일반식(I)의 화합물(더 특수하게는 R이 수소원자 또는 알킬 또는 알케닐기인)은 공지된 방법자체로써 산부가염으로 전환시킬 수 있다.Compounds of formula (I), more particularly wherein R is a hydrogen atom or an alkyl or alkenyl group, can be converted into acid addition salts by known methods themselves.

전술한 방법으로 얻은 일반식(I)의 디티에피노〔1,4〕〔2,3- C〕피를 유도체는 결정화 또는 크로마토그라피 같은 물리적 방법 또는 염의형성, 염의 결정화 및 알카리 매질에서의 염의 분해같은 화학적 방법으로 정제할 수 있다. 전술한 화학적 방법을 시행함에 있어서 염의 음이온의 성질은 중요하지 않으며 유일한 요구조건은 염이 윤곽이 뚜렷하고 쉽게 결정화할 수 있어야 한다는 것이다.The dithiepino [1,4] [2,3-C] pyrido derivatives of the general formula (I) obtained by the above-described method may be obtained by physical methods such as crystallization or chromatography or salt formation, salt crystallization and decomposition of salts in alkaline media. It can be purified by the same chemical method. The nature of the anions of the salts is not critical to the practice of the above-mentioned chemical methods and the only requirement is that the salts are contoured and easily crystallized.

일반식(I)의 화합물(디 특수하게는 R이 수소원자 또는 알킬 또는 알케닐기인)은 공지된 방법제로써 산부가염으로 전환 시킬 수 있다.Compounds of general formula (I), in which R in particular is a hydrogen atom or an alkyl or alkenyl group, can be converted into acid addition salts by known methods.

산부가염은 적당한 용매중에서 신규한 화합물에 산을 작용시킴으로써 제조할 수 있다. 유기용매로서는 알콜류, 케톤류, 에텔류 또는 염소화된 탄화수소등을 사용할 수 있다. 생성되는 염은 침전되며, 용액을 농축후 필요하다면 여과 또는 경사로 분리한다.Acid addition salts can be prepared by reacting the acid with the new compound in a suitable solvent. Alcohols, ketones, ethers or chlorinated hydrocarbons can be used as the organic solvent. The resulting salt precipitates out and the solution is concentrated and, if necessary, separated by filtration or decantation.

본 발명의 디티에피노〔1,4〕〔2,3- C〕피를 유도체 및 적당한 곳에는 그들의 산 부가염들이 중요한 약리적 성질을 갖고 있다. 그것들은 정신안정제, 항경련제, 이완제 및 수면제로서 특히 강력하다. 동물(쥐)에 있어서 1-100mg/kg(동물체중)의 용량으로 경구투여 했을때 특히 다음과 시험에서 강한 작용을 보였다;The derivatives of dithiepino [1,4] [2,3-C] blood of the present invention and, where appropriate, their acid addition salts have important pharmacological properties. They are particularly powerful as mental stabilizers, anticonvulsants, relaxers and sleeping pills. In animals (or rats), oral administration at a dose of 1-100 mg / kg (animal weight) showed a particularly strong effect in the following tests;

(i) J. Pharmacol 125,28(1959)에 기재된 티디쉬(Tedeshi)등의 기술과 유사한 기술에 따라 전기적 투쟁을 시켰을 때,(i) when an electrical struggle is made according to a technique similar to that of Tedeshi et al. described in J. Pharmacol 125,28 (1959),

(ii) J. Pharmacol, 81,402(1994)에 기재된 에버렛(Everett) 및 리챠드 (Rlchards)의 기술과 유사한 기술에 따라 펜테트라졸유발 경련을 일으켰을 때,(ii) when pentetrazole-induced convulsions are developed according to techniques similar to those of Everett and Richard et al., described in J. Pharmacol, 81,402 (1994);

(iii) J. Pharmacol ,106,319(1952)에 기재된 스윈야드(Swinyard)등의 기술에 따라 극량이상의 자극을 주었을 때,(iii) when a stimulus of more than a minimum was given according to the technique of Swinyard et al. described in J. Pharmacol, 106,319 (1952),

(ⅳ) Arzneimittel Forschung 23,683(1973)에 기재된 에프 발자기(F. Barzaghi)등의 기술과 유사한 기술에 따라 스트리크닌으로 처리시 사망률 및And (iii) mortality upon treatment with striknin according to techniques similar to those of F. Barzaghi et al., Described in Arzneimittel Forschung 23,683 (1973).

(ⅴ) Congres des Medecins Alienistes et Neurologistes Tours, 8th-13th June 1959에 기재된 쿨바저(Cour voisier)의 기술 및 Bulletin de la societe de Pharmacie de Lille NO.2,Jan 1967.p.7에 기재된 주르(Julou)의 기술에 따른 운동성 실험.(V) Convores des Medecins Alienistes et Neurologistes Tours, 8th-13th June 1959, the description of the Cour voisier, and Julou described in Bulletin de la societe de Pharmacie de Lille NO.2, Jan 1967.p.7. Mobility test according to the technique of).

더군다나, 본 발명의 화합물들은 독성이 낮다; 쥐에게 경구 투여시 LD50은 대체로 900mg/kg(동물체중)보다 더 컸다.Furthermore, the compounds of the invention are low in toxicity; When administered orally to rats, the LD 50 was generally greater than 900 mg / kg body weight.

본 발명중에서 보다 좋은 디티에피노〔1,4〕〔2,3- C〕피를 유도체는 A가 피리드-2-일 또는, 할로겐원자(염소가 더 좋다) 또는 C1-4의 알콕시기(메톡시기가 더 좋다)로 임의 치환된 1,8-나프티리딘-2-일기이며, R이 C1-4의 알킬기(메틸기가 더 좋다) 또는 C2-4의 알케닐기(알릴기가 더 좋다)인 일반식(I)의 화합물이다. 특히 흥미를 끄는 것 중에서는 다음 실시예 2,10,11 및 15에서의 생성물로 얻는 일반식(I)의 디티에피노 〔1,4〕〔2,3- C〕피를 유도체들이다.In the present invention, a better dithiepino [1,4] [2,3-C] pyridine derivative is A in which pyrid-2-yl or a halogen atom (preferably chlorine) or a C 1-4 alkoxy group. Is a 1,8-naphthyridin-2-yl group optionally substituted with a (methoxy group is better) and R is a C 1-4 alkyl group (preferably a methyl group) or a C 2-4 alkenyl group (preferably an allyl group) ) Is a compound of formula (I). Of particular interest are derivatives of dithiepino [1,4] [2,3-C] pis of general formula (I) obtained as products in the following examples 2, 10, 11 and 15.

치료목적을 위해서는, 일반식(I)의 디티에피노〔1,4〕〔2,3- C〕피를 유도체들이 그대로 또는 즉 염의 치료량에서 동물기관에 비교적 무해한 음이온을 함유하는 염(염산염, 황산염, 질산염, 인산염, 초산염, 프로피온산염, 호박산염,벤조산염, 푸타르산염, 말레산염, 주석산염, 테오필란-초산염, 살리실산염, 페놀프탈린염 및 메틸렌비스 -β-하이드록시나프로산염)의 형태로 함으로써 염기기 본래 갖고 있는 유용한 생리적 성질이 음이온에 기인하는 부작용에 의해 저하되지 않도록 비독성 산부가염의 형태로 사용할 수 있다.For therapeutic purposes, the salts of dithiepino [1,4] [2,3-C] blood of formula (I), as they are or that contain relatively negative anions, which are relatively harmless to animal organs in therapeutic amounts of salts (hydrochlorides, sulfates) , Nitrates, phosphates, acetates, propionates, succinates, benzoates, butyrates, maleates, tartarates, theophylan-acetates, salicylates, phenolphthalinates and methylenebis-β-hydroxynaproates) In the form of, it can be used in the form of non-toxic acid addition salt so that the useful physiological properties originally possessed by the base group are not lowered by side effects caused by anions.

다음의 무한한 실시예로 본 발명을 예시하고자 한다.The invention is illustrated by the following infinite examples.

[실시예]EXAMPLE

1-메틸피페라진(1.1g)을 7-(5-클로로피리드-2-일)-8-옥소-페녹시카보닐옥시-3,4,7,8-테트라하이드로-2H,6H-디티에피노〔1,4〕〔2,3-C〕피롤(1.6g)의 아세토니트릴(20cc) 현탁액에 가한다.1-Methylpiperazin (1.1 g) was added 7- (5-chloropyrid-2-yl) -8-oxo-phenoxycarbonyloxy-3,4,7,8-tetrahydro-2H, 6H-diti It is added to acetonitrile (20 cc) suspension of epino [1,4] [2,3-C] pyrrole (1.6 g).

생성된 현탁액을 약 20℃에서 20시간동안 교반한다. 아세토니트릴을 감압(20 mmHg)하에 증발시킨다. 결정성 잔사(2.4g, 융점 약 150℃)를 메틸렌 클로라이드 (40cc)에 녹인다.The resulting suspension is stirred at about 20 ° C. for 20 hours. Acetonitrile is evaporated under reduced pressure (20 mmHg). Crystalline residue (2.4 g, melting point about 150 ° C.) is dissolved in methylene chloride (40 cc).

메틸렌클로라이드 용액을 N-수산화나트륨 용액(40cc)으로 세척하고 0.1N수용성 메탄설폰산 용액(합계 200cc)으로 2회 추출한다. 산성수성추출물을 약 10N 수산화나트륨 용액을 가해 알칼리성으로 한다. 분리되는 오일을 메틸렌 클로라이드(합계 80cc)로 2회 추출한다. 유기용액을 증류수(합계 100cc)로 두번 세척하고, 무수황산 마그네슘상에서 건조시키고 증발시킨다. 생성물(1.6g ; 융점 153℃)을 비등 아세토니트릴 (4cc)에 녹이고, 비등 에탄올(14cc)을 가한다. 용액 2℃에서 2시간 동안 냉각시킨후, 그 결과 생성되는 결정을 여벌하고, 얼음을 채운 에탄올(5cc)로 세척하고 감압 (0.2,mmHg)하에서 건조시킨다. 156℃에서 녹는 7-(5-클로로피리드-2-일)-6-(4-메틸피페라진-1-일)-카보닐옥시-8-옥소-3,4,7,8-테트라하이드로-2H,6H-디티에피노〔1,4〕〔2,3- C〕피롤(0.7g)을 얻는다.The methylene chloride solution is washed with N-sodium hydroxide solution (40 cc) and extracted twice with 0.1 N aqueous methanesulfonic acid solution (200 cc total). The acidic aqueous extract is made alkaline by adding about 10N sodium hydroxide solution. The oil to be separated is extracted twice with methylene chloride (80 cc in total). The organic solution is washed twice with distilled water (total 100 cc), dried over anhydrous magnesium sulfate and evaporated. The product (1.6 g; melting point 153 ° C.) is dissolved in boiling acetonitrile (4 cc) and boiling ethanol (14 cc) is added. After cooling for 2 hours at 2 ° C., the resulting crystals are spared, washed with ice-filled ethanol (5 cc) and dried under reduced pressure (0.2, mmHg). 7- (5-chloropyrid-2-yl) -6- (4-methylpiperazin-1-yl) -carbonyloxy-8-oxo-3,4,7,8-tetrahydro soluble at 156 ° C -2H, 6H-dithiino [1,4] [2,3-C] pyrrole (0.7 g) is obtained.

7-(5-클로로피리드-2-일)-8-옥소-6-페녹시카보닐옥시-3,4,7,8-테트라하이드로-2H,6H-디티에피노〔1,4〕〔2,3- C〕피롤은 페닐클로로포르메이트(3.14g)를-10°-20℃에서 7-(5-클로로피리드-2-일)-6-하이드록시-8-옥소-3,4, 7 , 8-테트라하이드로-2H,6H-디티에피노〔1,4〕〔2,3- C〕피롤(210g)의 무수 피리딘(25cc) 용액에 작용시켜 제조할 수 있다.7- (5-chloropyrid-2-yl) -8-oxo-6-phenoxycarbonyloxy-3,4,7,8-tetrahydro-2H, 6H-dithi epino [1,4] [ 2,3-C] pyrrole was added phenylchloroformate (3.14g) at -10 ° -20 ° C and 7- (5-chloropyrid-2-yl) -6-hydroxy-8-oxo-3,4 , 7,8-tetrahydro-2H, 6H-dithiepino [1,4] [2,3-C] pyrrole (210 g) can be prepared by acting on anhydrous pyridine (25 cc) solution.

아세토니트릴(50cc)로 재결정한 후 173℃에서 녹는 7-(5-클로로피리드-2-일)-8-옥소-6-페녹시카보닐옥시-3,4,7,8-페트라하이드로-2H,6H-디티에피노〔1,4〕〔2,3- C〕피롤(1.73g)을 얻는다.7- (5-chloropyrid-2-yl) -8-oxo-6-phenoxycarbonyloxy-3,4,7,8-petrahydro- soluble at 173 ° C. after recrystallization with acetonitrile (50 cc) 2H, 6H-dithi epino [1,4] [2,3-C] pyrrole (1.73 g) is obtained.

전술한 실시예들의 과정에 따라 적절한 일반식(II)와 (Ⅲ)의 출발물질을 사용하여 또한 다음 일반식(I)의 생성물을 얻는다 :According to the procedure of the foregoing embodiments, using appropriate starting materials of the general formulas (II) and (III), the product of the following general formula (I) is also obtained:

6-(4-메틸피페라진-1-일)카보닐옥시-7-(4-니트로페닐)-8-옥소-3,4, 7,8-테트라하이드로-2H,6H-디티에피노〔1,4〕〔2,3-C〕피롤, 149℃에서 용해.6- (4-Methylpiperazin-1-yl) carbonyloxy-7- (4-nitrophenyl) -8-oxo-3,4, 7,8-tetrahydro-2H, 6H-dithiino [1 , 4] [2,3-C] pyrrole, dissolved at 149 ° C.

7-(5-클로로피리드-2-일)-6-(4-에틸피페라진-1-일)카복실옥시-8-옥소-3,4,7,8-테트라하이드로-2H,6H-디티에피노-〔1,4〕〔2,3-C〕피롤, 130℃에서 용해.7- (5-chloropyrid-2-yl) -6- (4-ethylpiperazin-1-yl) carboxyloxy-8-oxo-3,4,7,8-tetrahydro-2H, 6H-diti Epino- [1,4] [2,3-C] pyrrole, dissolved at 130 ° C.

6-(4-알릴피페라진-1-일)카보닐옥시-7-(5-클로로피리드-2-8-옥소-3,4,7,8-테트라하이드로-2H,6H-디티에피노-〔1,4〕〔2,3-C〕피롤, 139℃에서 용해.6- (4-allylpiperazin-1-yl) carbonyloxy-7- (5-chloropyrid-2-8-oxo-3,4,7,8-tetrahydro-2H, 6H-dithiino -[1,4] [2,3-C] pyrrole, dissolved at 139 ° C.

6-(4-메틸피페라진-1-일)카보닐옥시-7-(5-메틸피리드-2-일)-8-옥소-3,4,7,8-테트라하이드로-2H,6H-디티에피노〔1,4〕〔2,3-C〕피롤, 145℃에서 용해.6- (4-methylpiperazin-1-yl) carbonyloxy-7- (5-methylpyrid-2-yl) -8-oxo-3,4,7,8-tetrahydro-2H, 6H- Dithiepino [1,4] [2,3-C] pyrrole, dissolved at 145 ° C.

6-(4-메틸피페라진-1-일)카보닐옥소-7-(5-니트로피리드-2-일)-8-옥소-3,4,7,8-테트라하이드로-2H,6H-디티에피노-〔1,4〕〔2,3-C〕피롤, 182℃에서 용해.6- (4-Methylpiperazin-1-yl) carbonyloxo-7- (5-nitropyridyl-2-yl) -8-oxo-3,4,7,8-tetrahydro-2H, 6H- Dithiepino- [1,4] [2,3-C] pyrrole, dissolved at 182 ° C.

7-(7-클로로퀴놀-2-일)-6-(4-메틸피페라진-1-일)카보닐옥시-8-옥소-3,4,7,8-테트라하이드로-2H,6H-디티에피노-〔1,4〕〔2,3-C〕피롤, 염산염이 255℃에서 분해하며, 용해.7- (7-chloroquinol-2-yl) -6- (4-methylpiperazin-1-yl) carbonyloxy-8-oxo-3,4,7,8-tetrahydro-2H, 6H-diti Epino- [1,4] [2,3-C] pyrrole and hydrochloride decompose at 255 ° C and dissolve.

7-(7-메틸-1,8-나프티리딘-2-일)-6-(4-메틸피페라진-1-일)카보닐옥시-8-옥소-3,4,7,8-테트라하이드로-2H,6H-디티에피노〔1,4〕〔2,3-C〕피롤, 230℃에서 용해.7- (7-methyl-1,8-naphthyridin-2-yl) -6- (4-methylpiperazin-1-yl) carbonyloxy-8-oxo-3,4,7,8-tetrahydro -2H, 6H-dithiino [1,4] [2,3-C] pyrrole, dissolved at 230 ° C.

7-(7-메톡시-1,8-나프티리딘-2-일)-6-(4-메틸피페라진-1-일)카보닐옥시-8-옥소-3,4,7,8-테트라하이드로-2H,6H-디티에피노〔1,4〕〔2,3-C〕피롤, 215℃에서 용해.7- (7-methoxy-1,8-naphthyridin-2-yl) -6- (4-methylpiperazin-1-yl) carbonyloxy-8-oxo-3,4,7,8-tetra Hydro-2H, 6H-dithiepino [1,4] [2,3-C] pyrrole, dissolved at 215 ° C.

7-(7-클로로-1,8-나프티리딘-2-일)-6-(4-메틸피페라진-1-일)카보닐옥시-8-옥소-3,4,7,8-테트라하이드로-2H,6H-디티에피노〔1,4〕〔2,3-C〕피롤, 283℃에서 용해.7- (7-chloro-1,8-naphthyridin-2-yl) -6- (4-methylpiperazin-1-yl) carbonyloxy-8-oxo-3,4,7,8-tetrahydro -2H, 6H-dithiino [1,4] [2,3-C] pyrrole, dissolved at 283 ° C.

7-(7-클로로-1,8-나프티리딘-2-일)-6-(4-에틸피페라진-1-일)카보닐옥시-8-옥소-3,4,7,8-테트라하이드로-2H,6H-디티에피노〔1,4〕〔2,3- C〕피롤, 254℃에서 용해.7- (7-chloro-1,8-naphthyridin-2-yl) -6- (4-ethylpiperazin-1-yl) carbonyloxy-8-oxo-3,4,7,8-tetrahydro -2H, 6H-dithiino [1,4] [2,3-C] pyrrole, dissolved at 254 ° C.

7-(7-클로로-1,8-나프티리딘-2-일)-8-옥소-6-(4-프로필 피페라진-1-일)카보닐옥시-3,4,7,8-테트라하이드로-2H,6H-디티에피노〔1,4〕〔2,3- C〕 피롤-225℃에서 용해.7- (7-chloro-1,8-naphthyridin-2-yl) -8-oxo-6- (4-propyl piperazin-1-yl) carbonyloxy-3,4,7,8-tetrahydro -2H, 6H-dithiino [1,4] [2,3-C] pyrrole-dissolved at 225 ° C.

7-(7-클로로-1,8-나프티리딘-2-일)-6-(4-이소프로필피페라진-1-일)카보닐옥시-8-옥소-3,4,7,8-테트라하이드로-2H,6H-디티에피노〔1,4〕〔2,3- C〕피롤, 230℃에서 용해.7- (7-chloro-1,8-naphthyridin-2-yl) -6- (4-isopropylpiperazin-1-yl) carbonyloxy-8-oxo-3,4,7,8-tetra Hydro-2H, 6H-dithiepino [1,4] [2,3-C] pyrrole, dissolved at 230 ° C.

6-(4-알릴피페라진-1-일) 카보닐옥시-7-(7-클로로-1,8-나프티리딘-2-일)-8-옥소-3,4,7,8-테트라하이드로-2H,6H-디티에피노〔1,4〕〔2,3-C〕피롤, 226℃에서 용해.6- (4-allylpiperazin-1-yl) carbonyloxy-7- (7-chloro-1,8-naphthyridin-2-yl) -8-oxo-3,4,7,8-tetrahydro -2H, 6H-dithiino [1,4] [2,3-C] pyrrole, dissolved at 226 ° C.

6-(4-부티릴피페라진-1-일)카보닐옥시-7-(7-클로로-1,8-나프티리딘-2-일)-8-옥소-3,4,7,8-테트라하이드로-2H,6H-디티에피노〔1,4〕〔2,3-C〕피롤, 210℃ 와 230℃에서 용해.6- (4-butyrylpiperazin-1-yl) carbonyloxy-7- (7-chloro-1,8-naphthyridin-2-yl) -8-oxo-3,4,7,8-tetra Hydro-2H, 6H-dithiepino [1,4] [2,3-C] pyrrole, dissolved at 210 ° C and 230 ° C.

7-(7-클로로-1,8-나프티리딘-2-일)-8-옥소-6-(4-프로피오닐피페라진-1-일)카보닐옥시-3,4,7,8-테트라하이드로-2H,6H-디티에피노〔1,4〕〔2,3- C〕피롤, 246℃에서 용해.7- (7-chloro-1,8-naphthyridin-2-yl) -8-oxo-6- (4-propionylpiperazin-1-yl) carbonyloxy-3,4,7,8-tetra Hydro-2H, 6H-dithiepino [1,4] [2,3-C] pyrrole, dissolved at 246 ° C.

Claims (1)

다음 일반식(II)의 피페라진과 다음 일반식(Ⅲ)의 혼합탄산염을 반응시킴을 특징으로 하는 다음 일반식(I)의 디티에피노〔1,4〕〔2,3-C〕피롤유도체 및 그 산부가염의 제조방법.Dithiepino [1,4] [2,3-C] pyrrole derivatives of the following general formula (I) characterized by reacting piperazine of the following general formula (II) with a mixed carbonate of the following general formula (III) And a method for producing the acid addition salt thereof.
Figure kpo00008
Figure kpo00008
Figure kpo00009
Figure kpo00009
상기식에서 A는 페닐, 피리드-2-일, 퀴놀-2-일 또는 1,8-나프티리딘-2-일기이고, 각각 할로겐 원자, C1-4의 알킬기, C1-4의 알콕시기, 시아노기 또는 니트로기로 임의 치환될 수 있고 R은 수소원자 또는 C1-4의 알킬기, C2-4의 알케닐기 또는 C1-4의 알카노일기이고 Ar은 C1-4의 알킬기 또는 니트로기로 임의 치환되는 페닐기이다.Wherein A is phenyl, pyrid-2-yl, quinol-2-yl or 1,8-naphthyridin-2-yl group and each halogen atom, an alkoxy group of the alkyl group, C 1-4 of C 1-4, a cyano group or a nitro group can be optionally substituted, and R is an alkenyl group of Al or an alkyl group of C 1-4, C 2-4 a hydrogen atom or a C 1-4 alkanoyl group, and Ar is a C 1-4 alkyl or nitro It is an optionally substituted phenyl group.
KR1019810002605A 1977-02-17 1981-07-18 Process for preparing dithiepino(1,4)(2,3-c)pyrrole derivatives KR810001174B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019810002605A KR810001174B1 (en) 1977-02-17 1981-07-18 Process for preparing dithiepino(1,4)(2,3-c)pyrrole derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR7700357A KR810000933B1 (en) 1977-02-17 1977-02-17 Process for preparation of dithiepino(1,4)(2,3-c)pyrrole derivatives
KR1019810002605A KR810001174B1 (en) 1977-02-17 1981-07-18 Process for preparing dithiepino(1,4)(2,3-c)pyrrole derivatives

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR7700357A Division KR810000933B1 (en) 1977-02-17 1977-02-17 Process for preparation of dithiepino(1,4)(2,3-c)pyrrole derivatives

Publications (1)

Publication Number Publication Date
KR810001174B1 true KR810001174B1 (en) 1981-09-25

Family

ID=26625958

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019810002605A KR810001174B1 (en) 1977-02-17 1981-07-18 Process for preparing dithiepino(1,4)(2,3-c)pyrrole derivatives

Country Status (1)

Country Link
KR (1) KR810001174B1 (en)

Similar Documents

Publication Publication Date Title
SU820659A3 (en) Method of preparing 4-amino-5-alkylsulfonyl-o-anisamide derivatives,their salts,oxides,left-and right-rotational isomers (their variations)
FI73682C (en) FOERFARANDE FOER FRAMSTAELLNING AV ANTIVIRALT 9- (1,3-DIHYDROXI-2-PROPOXIMETYL) GUANIN SAMT MELLANPRODUKT.
SU1681728A3 (en) Method for preparation of n-(benzthiazolyl-2)amide derivatives of benzoic or thiazol-4-carboxylic acid
DE60316984T2 (en) BENZOYLSULFONAMIDE AS ANTITUMOR MEDIUM
DD282691A5 (en) PROCESS FOR THE PREPARATION OF CEPHALOSPORIN
SU845789A3 (en) Method of preparing d-7-/alpha-(4-oxy-6-methylnicotineamido)-alpha-(4-oxyphenyl)-acetamido/-3-(1-methyltetrazol-5-yl) thiomethyl-3-cephem-4-carboxylic acid
EP0038161A1 (en) 2,6-Diaminonebularines, their production and use
KR900003368B1 (en) Process for preparing novel indenothiazole derivatives
FI71319C (en) FRAMEWORK FOR THERAPEUTIC ADJUSTMENT OF THERAPEUTIC EQUIPMENT
JPH0873461A (en) Novel camptothecin derivative, method for producing the same and antitumor agent
KR810001174B1 (en) Process for preparing dithiepino(1,4)(2,3-c)pyrrole derivatives
US3426017A (en) Sulfonylurea compounds
EP0138490B1 (en) 4-alkyl methylenedioxy-2-1[H]-quinazolinones
GB1586709A (en) C3-carboxamido derivatives of vinblastine and alkaloids
FI62095C (en) FRUIT PROCEDURE FOR FRAMSTAELLNING AV NYA 1- OCH D1-6- / M- (ISOXAZOLE-3-CARBOXIAMIDO) PHENYL) -2,3,5,6-TETRAHYDROIMIDAZO (2,1-B) THIAZOLDERIVAT VILKA ANVAENDS SOM MASKMEDEL
US3547949A (en) Benzothiopyrone compounds
US3875176A (en) 2-benzoyl -3-amino-pyridines
KR810001133B1 (en) Process for preparing dithiepino(1,4)(2,3-c)pyrrole derivatives
US4124711A (en) Derivatives of dithiepino[1,4][2,3-C]pyrrole
US3988371A (en) Meta-[2-(benzylamino)-ethyl] benzoic acid amides
KR810000933B1 (en) Process for preparation of dithiepino(1,4)(2,3-c)pyrrole derivatives
JP3009716B2 (en) New camptothecin derivatives
US4327095A (en) Methoxy derivatives of 1,4-dithiepino-[2,3-c]-pyrrole
US3914379A (en) Substituted (nitrofuryl-acrylidene) hydrazines with antibacterial properties
CA1269984A (en) Dioxolobenzisoxazole derivatives and process for preparing the same